171 related articles for article (PubMed ID: 32319020)
21. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with recurrent oral squamous cell carcinoma treated with nivolumab.
Tachinami H; Tomihara K; Yamada SI; Ikeda A; Imaue S; Hirai H; Nakai H; Sonoda T; Kurohara K; Yoshioka Y; Hasegawa T; Naruse T; Niiyama T; Shimane T; Ueda M; Yanamoto S; Akashi M; Umeda M; Kurita H; Miyazaki A; Arai N; Hayashi R; Noguchi M
Br J Oral Maxillofac Surg; 2023 May; 61(4):320-326. PubMed ID: 37061418
[TBL] [Abstract][Full Text] [Related]
22. Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients.
Matsuki T; Okamoto I; Fushimi C; Sawabe M; Kawakita D; Sato H; Tsukahara K; Kondo T; Okada T; Tada Y; Miura K; Omura G; Yamashita T
Cancer Med; 2020 Jul; 9(14):5015-5024. PubMed ID: 32441463
[TBL] [Abstract][Full Text] [Related]
23. Nivolumab in gastric/gastroesophageal junction cancer: real-world data from UK Early Access to Medicines Scheme.
Soni M; Kiff C; Carroll R; Stein D; Saragoussi D; Nassar A; Maisey N; Tyas D
Future Oncol; 2021 Aug; 17(24):3163-3174. PubMed ID: 34098737
[TBL] [Abstract][Full Text] [Related]
24. Clinical Significance of Neutrophil-to-Lymphocyte Ratio/Serum Albumin Ratio in Patients With Metastatic Gastric or Gastroesophageal Junction Cancer Administered Trifluridine/Tipiracil.
Hashimoto I; Kano K; Onuma S; Suematsu H; Nagasawa S; Kanematsu K; Furusawa K; Hamaguchi T; Watanabe M; Hayashi K; Furuta M; Inokuchi Y; Machida N; Aoyama T; Yamada T; Rino Y; Ogata T; Oshima T
Anticancer Res; 2023 Apr; 43(4):1689-1697. PubMed ID: 36974783
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses.
Matsumoto T; Yamamoto Y; Kuriona Y; Okazaki U; Kimura S; Miura K; Tsuduki T; Watanabe T; Mastumoto Y; Takatani M
BMC Cancer; 2020 Jul; 20(1):684. PubMed ID: 32698781
[TBL] [Abstract][Full Text] [Related]
26. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab.
Simonaggio A; Elaidi R; Fournier L; Fabre E; Ferrari V; Borchiellini D; Thouvenin J; Barthelemy P; Thibault C; Tartour E; Oudard S; Vano YA
Cancer Immunol Immunother; 2020 Dec; 69(12):2513-2522. PubMed ID: 32561968
[TBL] [Abstract][Full Text] [Related]
27. Lymphocyte-to-Monocyte Ratio Is a Predictive Biomarker of Response to Treatment with Nivolumab for Gastric Cancer.
Tokumaru S; Koizumi T; Sekino Y; Takeuchi N; Nakata S; Miyagawa Y; Kitazawa M; Muranaka F; Nakamura S; Koyama M; Yamamoto Y; Ehara T; Hondo N; Soejima Y
Oncology; 2021; 99(10):632-640. PubMed ID: 34280933
[TBL] [Abstract][Full Text] [Related]
28. Examining the Efficacy of Nivolumab for Gastric Cancer Focusing on Using an Inflammation-based Prognostic Score: A Multicenter Retrospective Study.
Nakazawa N; Sohda M; Tateno K; Watanabe T; Kimura A; Kogure N; Hosaka H; Naganuma A; Sekiguchi M; Saito K; Ogata K; Sano A; Sakai M; Ogawa H; Shirabe K; Saeki H
Anticancer Res; 2023 Feb; 43(2):927-934. PubMed ID: 36697068
[TBL] [Abstract][Full Text] [Related]
29. Cancer Cachexia Reduces the Efficacy of Nivolumab Treatment in Patients With Advanced Gastric Cancer.
Fujii H; Makiyama A; Iihara H; Okumura N; Yamamoto S; Imai T; Arakawa S; Kobayashi R; Tanaka Y; Yoshida K; Suzuki A
Anticancer Res; 2020 Dec; 40(12):7067-7075. PubMed ID: 33288604
[TBL] [Abstract][Full Text] [Related]
30. Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma.
Ishihara H; Tachibana H; Takagi T; Kondo T; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Target Oncol; 2019 Aug; 14(4):453-463. PubMed ID: 31359231
[TBL] [Abstract][Full Text] [Related]
31. Pretreatment Neutrophil to Lymphocyte Ratio Independently Predicts Disease-specific Survival in Resectable Gastroesophageal Junction and Gastric Adenocarcinoma.
Wang SC; Chou JF; Strong VE; Brennan MF; Capanu M; Coit DG
Ann Surg; 2016 Feb; 263(2):292-7. PubMed ID: 25915915
[TBL] [Abstract][Full Text] [Related]
32. Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer.
Chau I; Le DT; Ott PA; Korytowsky B; Le H; Le TK; Zhang Y; Sanchez T; Maglinte GA; Laurie M; Abraham P; Patel D; Shangguan T
Gastric Cancer; 2020 Jan; 23(1):133-141. PubMed ID: 31549264
[TBL] [Abstract][Full Text] [Related]
33. Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer.
Sekine K; Kanda S; Goto Y; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Ohe Y
Lung Cancer; 2018 Oct; 124():179-188. PubMed ID: 30268458
[TBL] [Abstract][Full Text] [Related]
34. Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study.
Sano A; Sohda M; Nakazawa N; Ubukata Y; Kuriyama K; Kimura A; Kogure N; Hosaka H; Naganuma A; Sekiguchi M; Saito K; Ogata K; Sakai M; Ogawa H; Shirabe K; Saeki H
BMC Cancer; 2022 Jan; 22(1):22. PubMed ID: 34980017
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer.
Zhao G; Liu N; Wang S; Guo J; Song X; Qi Y; Qiu W; Lv J
Medicine (Baltimore); 2020 Mar; 99(10):e19405. PubMed ID: 32150090
[TBL] [Abstract][Full Text] [Related]
36. The neutrophil-to-lymphocyte ratio (NLR) predicts short-term and long-term outcomes in gastric cancer patients.
Miyamoto R; Inagawa S; Sano N; Tadano S; Adachi S; Yamamoto M
Eur J Surg Oncol; 2018 May; 44(5):607-612. PubMed ID: 29478743
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma.
Yamamoto Y; Matsuyama H; Matsumoto H; Sakano S; Fuji N; Oba K; Yamamoto M; Kamiryo Y; Hiragino T; Nagao K; Takai K; Aoki A
Jpn J Clin Oncol; 2020 Feb; 50(2):214-220. PubMed ID: 31755525
[TBL] [Abstract][Full Text] [Related]
38. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
[TBL] [Abstract][Full Text] [Related]
39. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab.
Nakaya A; Kurata T; Yoshioka H; Takeyasu Y; Niki M; Kibata K; Satsutani N; Ogata M; Miyara T; Nomura S
Int J Clin Oncol; 2018 Aug; 23(4):634-640. PubMed ID: 29442281
[TBL] [Abstract][Full Text] [Related]
40. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK; Boku N; Satoh T; Ryu MH; Chao Y; Kato K; Chung HC; Chen JS; Muro K; Kang WK; Yeh KH; Yoshikawa T; Oh SC; Bai LY; Tamura T; Lee KW; Hamamoto Y; Kim JG; Chin K; Oh DY; Minashi K; Cho JY; Tsuda M; Chen LT
Lancet; 2017 Dec; 390(10111):2461-2471. PubMed ID: 28993052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
